Concepts (248)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anticoagulants | 22 | 2024 | 57 | 3.950 |
Why?
|
| Venous Thromboembolism | 11 | 2023 | 27 | 3.060 |
Why?
|
| Thrombosis | 8 | 2024 | 47 | 2.320 |
Why?
|
| Venous Thrombosis | 6 | 2023 | 14 | 1.410 |
Why?
|
| Hemorrhage | 9 | 2023 | 72 | 1.390 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 6 | 2024 | 19 | 1.220 |
Why?
|
| Thrombocytopenia | 3 | 2022 | 11 | 1.130 |
Why?
|
| International Normalized Ratio | 7 | 2021 | 17 | 1.110 |
Why?
|
| Enoxaparin | 7 | 2024 | 14 | 1.100 |
Why?
|
| Humans | 54 | 2024 | 14537 | 1.080 |
Why?
|
| Warfarin | 6 | 2024 | 19 | 1.080 |
Why?
|
| Altitude | 1 | 2024 | 9 | 0.930 |
Why?
|
| Female | 34 | 2024 | 9103 | 0.850 |
Why?
|
| Enzyme Replacement Therapy | 1 | 2022 | 2 | 0.790 |
Why?
|
| Rare Diseases | 1 | 2022 | 5 | 0.790 |
Why?
|
| Glucosylceramidase | 1 | 2022 | 3 | 0.790 |
Why?
|
| Gaucher Disease | 1 | 2022 | 4 | 0.790 |
Why?
|
| Risk Factors | 13 | 2024 | 1475 | 0.720 |
Why?
|
| Adult | 22 | 2024 | 5913 | 0.700 |
Why?
|
| Practice Guidelines as Topic | 4 | 2016 | 127 | 0.680 |
Why?
|
| Middle Aged | 17 | 2024 | 3601 | 0.670 |
Why?
|
| Thromboembolism | 4 | 2021 | 10 | 0.640 |
Why?
|
| Pregnancy Complications | 1 | 2019 | 55 | 0.640 |
Why?
|
| South Africa | 21 | 2024 | 7596 | 0.600 |
Why?
|
| Pregnancy Complications, Cardiovascular | 3 | 2024 | 34 | 0.590 |
Why?
|
| Ambulatory Care | 1 | 2018 | 54 | 0.590 |
Why?
|
| Atrial Fibrillation | 4 | 2024 | 7 | 0.590 |
Why?
|
| Male | 19 | 2024 | 6754 | 0.590 |
Why?
|
| Pregnancy | 13 | 2024 | 1862 | 0.540 |
Why?
|
| Aged | 11 | 2024 | 1740 | 0.530 |
Why?
|
| HIV Infections | 10 | 2023 | 5097 | 0.520 |
Why?
|
| Heparin, Low-Molecular-Weight | 4 | 2023 | 11 | 0.500 |
Why?
|
| Stroke | 4 | 2024 | 62 | 0.460 |
Why?
|
| Drug Monitoring | 3 | 2013 | 55 | 0.460 |
Why?
|
| Foot | 1 | 2013 | 5 | 0.450 |
Why?
|
| Casts, Surgical | 1 | 2013 | 2 | 0.450 |
Why?
|
| Ankle | 1 | 2013 | 3 | 0.450 |
Why?
|
| Orthopedic Procedures | 1 | 2013 | 5 | 0.440 |
Why?
|
| Blood Coagulation | 5 | 2012 | 29 | 0.430 |
Why?
|
| Vena Cava Filters | 1 | 2013 | 4 | 0.430 |
Why?
|
| Preoperative Care | 1 | 2013 | 9 | 0.420 |
Why?
|
| Secondary Prevention | 1 | 2013 | 20 | 0.420 |
Why?
|
| Pulmonary Embolism | 2 | 2012 | 7 | 0.390 |
Why?
|
| Heart Valve Prosthesis | 3 | 2024 | 9 | 0.390 |
Why?
|
| Vitamin K | 4 | 2024 | 4 | 0.380 |
Why?
|
| Hemostatics | 2 | 2022 | 17 | 0.380 |
Why?
|
| von Willebrand Factor | 3 | 2024 | 21 | 0.370 |
Why?
|
| Rivaroxaban | 3 | 2024 | 6 | 0.370 |
Why?
|
| Registries | 5 | 2024 | 91 | 0.360 |
Why?
|
| Endothelial Cells | 1 | 2010 | 14 | 0.360 |
Why?
|
| Vaccines | 2 | 2022 | 86 | 0.360 |
Why?
|
| Lower Extremity | 1 | 2010 | 10 | 0.360 |
Why?
|
| Biomarkers | 5 | 2023 | 327 | 0.350 |
Why?
|
| von Willebrand Disease, Type 1 | 1 | 2010 | 1 | 0.340 |
Why?
|
| Factor V | 1 | 2010 | 10 | 0.340 |
Why?
|
| Pregnancy Complications, Hematologic | 1 | 2010 | 9 | 0.340 |
Why?
|
| Hemoglobins | 3 | 2022 | 40 | 0.340 |
Why?
|
| Prothrombin Time | 2 | 2006 | 15 | 0.330 |
Why?
|
| Aspirin | 3 | 2019 | 15 | 0.320 |
Why?
|
| Platelet Aggregation Inhibitors | 3 | 2019 | 12 | 0.310 |
Why?
|
| Thrombelastography | 2 | 2024 | 6 | 0.310 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2019 | 125 | 0.300 |
Why?
|
| Longitudinal Studies | 3 | 2023 | 435 | 0.300 |
Why?
|
| Drug Eruptions | 1 | 2007 | 3 | 0.300 |
Why?
|
| Hospitals, Special | 1 | 2007 | 4 | 0.300 |
Why?
|
| Prothrombin | 1 | 2007 | 8 | 0.300 |
Why?
|
| Fibrinolytic Agents | 1 | 2007 | 7 | 0.290 |
Why?
|
| Pregnancy Outcome | 3 | 2024 | 117 | 0.280 |
Why?
|
| Young Adult | 6 | 2024 | 2498 | 0.280 |
Why?
|
| Risk Assessment | 4 | 2024 | 225 | 0.270 |
Why?
|
| Anti-Retroviral Agents | 1 | 2010 | 551 | 0.260 |
Why?
|
| Adolescent | 5 | 2022 | 2985 | 0.250 |
Why?
|
| Prospective Studies | 7 | 2019 | 1160 | 0.240 |
Why?
|
| Air Travel | 1 | 2024 | 4 | 0.230 |
Why?
|
| Oximetry | 1 | 2024 | 6 | 0.230 |
Why?
|
| Pyrazoles | 1 | 2024 | 5 | 0.230 |
Why?
|
| Healthy Volunteers | 1 | 2024 | 18 | 0.230 |
Why?
|
| Factor Xa Inhibitors | 1 | 2024 | 3 | 0.230 |
Why?
|
| Blood Preservation | 1 | 2004 | 3 | 0.230 |
Why?
|
| Follow-Up Studies | 3 | 2018 | 370 | 0.230 |
Why?
|
| Patient Selection | 1 | 2024 | 40 | 0.230 |
Why?
|
| Plasma | 1 | 2004 | 39 | 0.230 |
Why?
|
| Temperature | 1 | 2004 | 56 | 0.230 |
Why?
|
| Time Factors | 3 | 2013 | 507 | 0.220 |
Why?
|
| Postthrombotic Syndrome | 1 | 2023 | 1 | 0.220 |
Why?
|
| Pyridones | 1 | 2024 | 100 | 0.220 |
Why?
|
| Aircraft | 1 | 2003 | 3 | 0.220 |
Why?
|
| Travel | 1 | 2003 | 21 | 0.220 |
Why?
|
| Embolism | 1 | 2023 | 4 | 0.210 |
Why?
|
| Treatment Outcome | 5 | 2024 | 889 | 0.210 |
Why?
|
| Thiophenes | 2 | 2013 | 4 | 0.210 |
Why?
|
| Morpholines | 2 | 2013 | 5 | 0.210 |
Why?
|
| Fibrinolysis | 1 | 2022 | 3 | 0.200 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2022 | 5 | 0.200 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2022 | 8 | 0.200 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 2022 | 14 | 0.200 |
Why?
|
| Case-Control Studies | 5 | 2021 | 480 | 0.200 |
Why?
|
| Splenectomy | 1 | 2022 | 3 | 0.200 |
Why?
|
| Antiphospholipid Syndrome | 1 | 2022 | 5 | 0.200 |
Why?
|
| Platelet Activation | 2 | 2021 | 17 | 0.200 |
Why?
|
| Machine Learning | 1 | 2021 | 22 | 0.190 |
Why?
|
| Anemia | 1 | 2022 | 41 | 0.190 |
Why?
|
| Occupational Diseases | 1 | 2002 | 40 | 0.190 |
Why?
|
| Heparin | 1 | 2021 | 5 | 0.190 |
Why?
|
| Coronavirus | 1 | 2021 | 14 | 0.180 |
Why?
|
| Genotype | 1 | 2022 | 442 | 0.170 |
Why?
|
| Retrospective Studies | 5 | 2024 | 799 | 0.170 |
Why?
|
| Cardiovascular Diseases | 1 | 2023 | 237 | 0.170 |
Why?
|
| Health Services Accessibility | 1 | 2022 | 280 | 0.160 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 239 | 0.160 |
Why?
|
| Erythrocyte Indices | 1 | 2018 | 7 | 0.160 |
Why?
|
| Platelet Aggregation | 3 | 2007 | 12 | 0.160 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2018 | 21 | 0.150 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2018 | 69 | 0.140 |
Why?
|
| Infant | 2 | 2022 | 2244 | 0.140 |
Why?
|
| Child | 2 | 2022 | 2242 | 0.140 |
Why?
|
| Ultrasonography | 2 | 2010 | 77 | 0.140 |
Why?
|
| Child, Preschool | 1 | 2022 | 1748 | 0.140 |
Why?
|
| Administration, Oral | 4 | 2024 | 127 | 0.140 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2021 | 529 | 0.130 |
Why?
|
| Reproducibility of Results | 3 | 2021 | 217 | 0.130 |
Why?
|
| Disease Management | 2 | 2013 | 74 | 0.120 |
Why?
|
| Aged, 80 and over | 2 | 2013 | 468 | 0.120 |
Why?
|
| Drug Therapy, Combination | 2 | 2012 | 279 | 0.110 |
Why?
|
| Inflammation | 2 | 2022 | 104 | 0.110 |
Why?
|
| Incidence | 3 | 2023 | 685 | 0.110 |
Why?
|
| Dabigatran | 1 | 2013 | 3 | 0.110 |
Why?
|
| beta-Alanine | 1 | 2013 | 3 | 0.110 |
Why?
|
| Benzimidazoles | 1 | 2013 | 13 | 0.110 |
Why?
|
| Drug Substitution | 1 | 2013 | 33 | 0.100 |
Why?
|
| Chemoprevention | 1 | 2013 | 33 | 0.100 |
Why?
|
| ADAMTS13 Protein | 2 | 2022 | 8 | 0.100 |
Why?
|
| Sodium Tetradecyl Sulfate | 1 | 1992 | 1 | 0.100 |
Why?
|
| Sclerosing Solutions | 1 | 1992 | 2 | 0.100 |
Why?
|
| Esophageal and Gastric Varices | 1 | 1992 | 2 | 0.100 |
Why?
|
| Platelet Count | 2 | 2021 | 14 | 0.100 |
Why?
|
| Pregnant Women | 2 | 2023 | 89 | 0.100 |
Why?
|
| Drug Delivery Systems | 1 | 2013 | 252 | 0.090 |
Why?
|
| Health Personnel | 2 | 2024 | 231 | 0.090 |
Why?
|
| Protein S | 1 | 2010 | 3 | 0.090 |
Why?
|
| Protein C | 1 | 2010 | 4 | 0.090 |
Why?
|
| Infant, Newborn | 2 | 2022 | 1479 | 0.090 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 45 | 0.090 |
Why?
|
| HIV | 2 | 2023 | 380 | 0.080 |
Why?
|
| Medicine in the Arts | 1 | 2009 | 3 | 0.080 |
Why?
|
| Intracranial Thrombosis | 1 | 2008 | 1 | 0.080 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2010 | 656 | 0.080 |
Why?
|
| Cortisone | 1 | 2007 | 1 | 0.070 |
Why?
|
| Ointments | 1 | 2007 | 1 | 0.070 |
Why?
|
| Nadroparin | 1 | 2007 | 1 | 0.070 |
Why?
|
| Injections, Subcutaneous | 1 | 2007 | 22 | 0.070 |
Why?
|
| Congresses as Topic | 1 | 2007 | 20 | 0.070 |
Why?
|
| Societies, Medical | 1 | 2007 | 26 | 0.070 |
Why?
|
| Patient Education as Topic | 1 | 2007 | 48 | 0.070 |
Why?
|
| Polysaccharides | 1 | 2007 | 45 | 0.070 |
Why?
|
| Blood Platelets | 2 | 2021 | 30 | 0.070 |
Why?
|
| Aortic Valve | 1 | 2006 | 1 | 0.070 |
Why?
|
| Mitral Valve | 1 | 2006 | 12 | 0.070 |
Why?
|
| Viral Load | 1 | 2010 | 819 | 0.070 |
Why?
|
| Thromboplastin | 2 | 2004 | 9 | 0.060 |
Why?
|
| Ischemic Attack, Transient | 1 | 2005 | 2 | 0.060 |
Why?
|
| Blood Sedimentation | 1 | 2005 | 12 | 0.060 |
Why?
|
| Cross-Sectional Studies | 2 | 2022 | 1422 | 0.060 |
Why?
|
| Sex Factors | 2 | 2021 | 227 | 0.060 |
Why?
|
| Bioprosthesis | 1 | 2024 | 8 | 0.060 |
Why?
|
| Abortion, Spontaneous | 1 | 2024 | 15 | 0.060 |
Why?
|
| Age Factors | 2 | 2021 | 370 | 0.060 |
Why?
|
| Dimerization | 1 | 2004 | 4 | 0.060 |
Why?
|
| Partial Thromboplastin Time | 1 | 2004 | 13 | 0.060 |
Why?
|
| Fibrinogen | 1 | 2004 | 10 | 0.060 |
Why?
|
| Freezing | 1 | 2004 | 6 | 0.060 |
Why?
|
| Phlebotomy | 1 | 2003 | 6 | 0.050 |
Why?
|
| Leg | 1 | 2003 | 21 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2024 | 244 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2023 | 44 | 0.050 |
Why?
|
| Regression Analysis | 1 | 2003 | 133 | 0.050 |
Why?
|
| Interleukin-6 | 1 | 2023 | 51 | 0.050 |
Why?
|
| Lactate Dehydrogenases | 1 | 2022 | 4 | 0.050 |
Why?
|
| Hemolysis | 1 | 2022 | 7 | 0.050 |
Why?
|
| Acute-Phase Proteins | 1 | 2022 | 14 | 0.050 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2022 | 3 | 0.050 |
Why?
|
| Specimen Handling | 1 | 2003 | 105 | 0.050 |
Why?
|
| Aerospace Medicine | 1 | 2002 | 1 | 0.050 |
Why?
|
| Drinking | 1 | 2002 | 1 | 0.050 |
Why?
|
| Placenta | 1 | 2022 | 44 | 0.050 |
Why?
|
| Hematocrit | 1 | 2002 | 6 | 0.050 |
Why?
|
| Outpatients | 1 | 2022 | 38 | 0.050 |
Why?
|
| Leukocyte Count | 1 | 2002 | 24 | 0.050 |
Why?
|
| Standard of Care | 1 | 2022 | 30 | 0.050 |
Why?
|
| Posture | 1 | 2002 | 16 | 0.050 |
Why?
|
| beta 2-Glycoprotein I | 1 | 2022 | 4 | 0.050 |
Why?
|
| Lupus Coagulation Inhibitor | 1 | 2022 | 4 | 0.050 |
Why?
|
| Antibodies, Antiphospholipid | 1 | 2022 | 5 | 0.050 |
Why?
|
| Antibodies, Anticardiolipin | 1 | 2022 | 9 | 0.050 |
Why?
|
| Immunoglobulin M | 1 | 2022 | 24 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2018 | 385 | 0.050 |
Why?
|
| Drug Dosage Calculations | 1 | 2021 | 8 | 0.050 |
Why?
|
| Simvastatin | 1 | 2021 | 10 | 0.050 |
Why?
|
| Mean Platelet Volume | 1 | 2021 | 3 | 0.050 |
Why?
|
| Alcohol Drinking | 1 | 2002 | 55 | 0.050 |
Why?
|
| Antigens | 1 | 2021 | 11 | 0.050 |
Why?
|
| Models, Biological | 1 | 2021 | 77 | 0.050 |
Why?
|
| Algorithms | 1 | 2021 | 106 | 0.050 |
Why?
|
| Body Weight | 1 | 2021 | 111 | 0.050 |
Why?
|
| Prevalence | 2 | 2019 | 1192 | 0.040 |
Why?
|
| Recurrence | 2 | 2012 | 29 | 0.040 |
Why?
|
| Africa South of the Sahara | 1 | 2021 | 353 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2022 | 231 | 0.040 |
Why?
|
| Erythrocyte Count | 1 | 2018 | 4 | 0.040 |
Why?
|
| Transferrin | 1 | 2018 | 5 | 0.040 |
Why?
|
| Reticulocytes | 1 | 2018 | 5 | 0.040 |
Why?
|
| Ferritins | 1 | 2018 | 23 | 0.040 |
Why?
|
| Iron | 1 | 2018 | 32 | 0.040 |
Why?
|
| Postpartum Period | 1 | 2019 | 85 | 0.040 |
Why?
|
| Pandemics | 1 | 2021 | 296 | 0.040 |
Why?
|
| Postpartum Hemorrhage | 1 | 2019 | 75 | 0.040 |
Why?
|
| Antiplatyhelmintic Agents | 1 | 2016 | 1 | 0.030 |
Why?
|
| Blood Substitutes | 1 | 2016 | 2 | 0.030 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2016 | 2 | 0.030 |
Why?
|
| Erythrocyte Transfusion | 1 | 2016 | 6 | 0.030 |
Why?
|
| Oxygen | 1 | 2016 | 25 | 0.030 |
Why?
|
| Cattle | 1 | 2016 | 28 | 0.030 |
Why?
|
| Consensus | 1 | 2016 | 62 | 0.030 |
Why?
|
| Fluoxetine | 1 | 1995 | 2 | 0.030 |
Why?
|
| Depressive Disorder | 1 | 1995 | 10 | 0.030 |
Why?
|
| Hemostasis | 1 | 1995 | 15 | 0.030 |
Why?
|
| Animals | 1 | 2016 | 1081 | 0.030 |
Why?
|
| Umbilical Veins | 1 | 1992 | 3 | 0.020 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 1992 | 34 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 106 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 1992 | 29 | 0.020 |
Why?
|
| Heart Valve Diseases | 1 | 2010 | 6 | 0.020 |
Why?
|
| Drug Resistance | 1 | 2008 | 35 | 0.020 |
Why?
|
| Reference Values | 1 | 2007 | 64 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2007 | 64 | 0.020 |
Why?
|
| Monitoring, Physiologic | 1 | 2007 | 25 | 0.020 |
Why?
|
| HIV Seroprevalence | 1 | 2007 | 15 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2006 | 156 | 0.020 |
Why?
|
| Probability | 1 | 2005 | 27 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2005 | 38 | 0.020 |
Why?
|
| Blood Coagulation Tests | 1 | 2005 | 24 | 0.020 |
Why?
|
| Survival Rate | 1 | 2005 | 96 | 0.020 |
Why?
|
| Prognosis | 1 | 2005 | 199 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2005 | 253 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2005 | 967 | 0.010 |
Why?
|
| Bleeding Time | 1 | 1995 | 1 | 0.010 |
Why?
|
| Blood Coagulation Factors | 1 | 1995 | 16 | 0.010 |
Why?
|
| Pilot Projects | 1 | 1995 | 179 | 0.010 |
Why?
|